Health

Remdesivir cuts need for medical ventilation by 50pc in Covid patients:Study

Shawdesh Desk: New research from a trial involving 52 Canadian hospitals indicates use of the antiviral Remdesivir could reduce the need for medical ventilation by nearly 50% in patients hospitalised

Your eyes hold the key to your true biological age, study finds

Shawdesh desk: The eyes may offer a “window into the soul,” as poets say, but they also have a lot to say about your health. Dry eyes can be a

One in 10 Covid-19 patients may still infect after quarantine period: Study

Shawdesh Desk: One in ten people may still be infectious for SARS-CoV-2, the virus that causes COVID-19, after the 10 day quarantine period, according to a study. The research, published

Researchers in Sweden identify gene variant that protects against Covid

Shawdesh desk: Researchers have identified a specific gene variant that protects against severe COVID-19 infection. An international team led by researchers at Karolinska Institutet in Sweden pinpointed the variant by

Sputnik V effective against omicron variant: RDIF

Shawdesh DEsk: Russia’s Sputnik V anti-coronavirus vaccine has proven a good level of efficacy against the omicron variant of the novel coronavirus, Russian Direct Investment Fund (RDIF) head Kirill Dmitriev

Japanese researchers 1st to use iPS cells to repair spinal cord injury

Shawdesh desk: Japanese researchers at Tokyo’s Keio University on Friday said it has conducted the world’s first clinical test involving the transplant of cells developed from iPS (induced pluripotent stem)

Covid-19: Common cold may give some protection: Study

Shawdesh Desk: Natural defences against a common cold could offer some protection against Covid-19, too, research suggests. The small-scale study, published in Nature Communications, involved 52 individuals who lived with

Pfizer expects Omicron vaccine to be ready in March

Shawdesh desk: Pfizer expects a Covid-19 vaccine targeting the Omicron variant to be ready in March, the company’s head said Monday. Pfizer Chief Executive Officer Albert Bourla told CNBC that